Up a level |
Burnett, Alan K, Das Gupta, Emma, Knapper, Steve, Khwaja, Asim, Sweeney, Marion, Kjeldsen, Lars, Hawkins, Timothy, Betteridge, Sophie E, Cahalin, Paul, Clark, Richard E ORCID: 0000-0002-1261-3299 et al (show 2 more authors)
(2018)
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.
HAEMATOLOGICA, 103 (10).
pp. 1654-1661.
Burnett, Alan K, Russell, Nigel H, Hills, Robert K, Knapper, Stephen, Freeman, Sylvie, Huntly, Brian, Clark, Richard E ORCID: 0000-0002-1261-3299, Thomas, Ian F, Kjeldsen, Lars, McMullin, Mary Frances et al (show 3 more authors)
(2020)
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39 (8).
JCO2001170-JCO2001170.
Russell, Nigel H, Hills, Robert K, Thomas, Abin, Thomas, Ian, Kjeldsen, Lars, Dennis, Mike, Craddock, Charles, Freeman, Sylvie, Clark, Richard E ORCID: 0000-0002-1261-3299 and Burnett, Alan K
(2022)
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial.
HAEMATOLOGICA, 107 (7).
pp. 1518-1527.
Ferguson, Paul, Hills, Robert K, Grech, Angela, Betteridge, Sophie, Kjeldsen, Lars, Dennis, Michael, Vyas, Paresh, Goldstone, Anthony H, Milligan, Donald, Clark, Richard E ORCID: 0000-0002-1261-3299 et al (show 2 more authors)
(2016)
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.
HAEMATOLOGICA, 101 (11).
pp. 1351-1358.